BETHLEHEM, Pa. -- B. Braun Medical Inc. today announced that it received FDA approval for CefTRIaxONE in the DUPLEX® Drug Delivery System. The availability of CefTRIaxONE, a standard intravenous antibiotic preparation, helps clinicians comply with Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and USP <797> Guidelines that specify medicines should be dispensed in their "most ready-to-use form."
No admixing or thawing is required as each DUPLEX® Drug Delivery System comes complete with drug and diluent in a convenient ready-to-use bag stored at room temperature. With CefTRIaxONE in DUPLEX®, doses can be stored conveniently and are immediately available for emergency IV purposes. B. Braun is proud to have received approval for an additional drug, CefTRIaxONE in the DUPLEX® Drug Delivery System once the current patent expires.
DUPLEX® is a unique closed-system designed to simplify intravenous antibiotic delivery to patients, reduce the risk of medication errors, reduce drug waste and eliminate pharmacy labor required during IV antibiotic delivery preparation.
Features of the DUPLEX® Drug Delivery System for admixing include:
-- Closed system pre-filled with accurate drug and diluent doses in a sealed two-chamber IV bag. No hoods required
-- Caregiver simply squeezes bag to mix the drug and diluent at patient's bedside
--Barcode references final admixture to help ensure correct drug
-- Stores at room temperature
-- PVC-free, DEHP-free, and latex-free
-- Tall man labeling helps to differentiate the drugs in the Duplex Drug
Delivery System
The DUPLEX® System consists of a pre-filled, PVC-free, DEHP-free, and latex-free IV bag containing proper doses of drug and diluent in different compartments separated by a quick release seal. The caregiver simply squeezes the bag to mix the drug and diluent just prior to administration. The DUPLEX® System is equipped with a UCC/EAN-128 barcode that references the final admixture and can be used to reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.
Source: B. Braun
The Latest on CLABSIs and CAUTIs: Evidence-Based Approaches for Infection Prevention
February 27th 2025Health care–associated infections like CLABSIs and CAUTIs threaten patient safety. Learn evidence-based strategies, new technologies, and prevention protocols to reduce these infections and improve outcomes.
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.
The Hidden Dangers of Hospital Ventilation: Are We Spreading Viruses Further?
January 31st 2025New research reveals hospital ventilation and air purifiers may unintentionally spread viral particles, increasing infection risks. Infection preventionists must rethink airflow strategies to protect patients and staff.
Alcohol-Based Antiseptics Show Promise for Nasal Decolonization and SSI Prevention
January 23rd 2025A meta-analysis found alcohol-based antiseptics significantly reduce Staphylococcus aureus-related surgical site infections (SSIs), demonstrating efficacy comparable to mupirocin and iodophor, supporting their expanded use in infection prevention strategies.